Evoke Pharma Inc (NAS:EVOK)
$ 4.3501 -0.0799 (-1.8%) Market Cap: 6.46 Mil Enterprise Value: 244,000.00 PE Ratio: 0 PB Ratio: 0.89 GF Score: 44/100

Q4 2023 Evoke Pharma Inc Earnings Call Transcript

Mar 14, 2024 / 08:30PM GMT
Release Date Price: $8.1 (+5.24%)
Operator

Good afternoon and welcome to the Evoke Pharma fourth-quarter and full-year 2023 earnings conference call. (Operator Instructions) I will now turn the call over to Daniel Kontoh-Boateng. Please go ahead, sir.

Daniel Kontoh;Boateng
Evoke Pharma - Investor Relations

Good afternoon, and thank you for participating in the Evoke Pharma's conference call and webcast today. With me today are Dave Gonyer, Evoke's Chief Executive Officer, Chris Quesenberry, GIMOTI's Chief Commercial Officer from Eversana; and Matt DâOnofrio, Evoke's President and Chief Operating Officer.

By now, you should have a copy of the press release we issued earlier. If not, it is available on the Investor Relations page of our website at evokepharma.com. We encourage everyone to read today's press release, as well as in both annual report on Form 10-K, which is now filed with the SEC. The company's Form 10-K and earnings release are also available on the Evoke's website.

Please note that certain information discussed on the call today is covered under the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot